Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Other financing activities (2020 - 2025)

Gain Therapeutics (GANX) has 4 years of Other financing activities data on record, last reported at $460793.0 in Q3 2025.

  • For Q3 2025, Other financing activities rose 30.9% year-over-year to $460793.0; the TTM value through Sep 2025 reached $3.5 million, up 80.01%, while the annual FY2024 figure was $2.3 million, 29.16% down from the prior year.
  • Other financing activities reached $460793.0 in Q3 2025 per GANX's latest filing, down from $530499.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $2.1 million in Q4 2024 and bottomed at $145473.0 in Q1 2024.
  • Average Other financing activities over 3 years is $695403.0, with a median of $460793.0 recorded in 2025.
  • The widest YoY moves for Other financing activities: up 190.88% in 2025, down 62.98% in 2025.
  • A 3-year view of Other financing activities shows it stood at $213795.0 in 2021, then soared by 863.7% to $2.1 million in 2024, then tumbled by 77.64% to $460793.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other financing activities were $460793.0 in Q3 2025, $530499.0 in Q2 2025, and $423145.0 in Q1 2025.